Site Listing

Please choose the site that is most convenient for you

Study Name: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrin
480 locations found